News: The Prickly Debate on Germline Gene Therapy, and Moving It Forward |
In 2016, a healthy baby boy came screaming into the world in a Mexican clinic. Harboring DNA from three parents, the baby had had his genes dramatically altered while still an embryo. Without the treatment, an inheritable neurological disorder would’ve killed him before the age of three. Two years later across the world in China, two girls, also as embryos, had their genes edited using CRISPR to make them (theoretically) resistant to HIV infection. The edits didn’t hit their intended target—instead, the girls may be more prone to infections, have altered brain functions, and even experience earlier deaths. Read more... |
Conference: 2nd Annual Hemophilia Drug Development Summit |
With the recent Hemlibra approval and the gene therapy revolution, we are seeing a much needed race to innovate more effective, long-lasting and curative therapies for hemophilia and acquired bleeding disorders. As such, the 2nd Annual Hemophilia Drug Development Summit, 20-22 August in Boston, remains dedicated to helping large pharma and biotech overcome translational research hurdles and deliver patients more clinically effective therapies and treatment solutions that dramatically improve patient outcomes and quality of life. Read more... |
Conference: CAR-TCR Summit |
Targeting solid tumors with CAR and TCR therapies has seen rapidly growing interest, effort and activity with 196 CAR-T and 77 TCR trials currently targeting solid tumor disease indications. Join the world’s leading CAR-TCR community at the CAR-TCR Summit, 10-13 September in Boston, and spend up to 4 days exploring the largest opportunities in this field. With 6 dedicated tracks spanning the end-to-end development pipeline, your whole team can leave with tangible actions to advance your therapies.
Read more... |
Conferences |
- |
20 - 23 July 2019, The 25th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Tokyo, Japan |
- |
23 - 25 July 2019, 2nd Neuropsychiatric Drug Development NDD meeting - Neural Gene Therapy, Boston, MA |
- |
12 - 16 August 2019, The Bioprocessing Summit 2019, Boston, MA |
- |
13 - 15 August 2019, Blood-Brain Barrier Delivery Summit (B3DD) - Gene delivery, Boston, MA |
- |
20 - 22 August 2019, 2nd Annual Hemophilia Drug Development Summit - Gene Therapy Drugs, Boston, MA |
- |
9 - 12 September 2019, Cell & Gene Therapy Manufacturing and Commercialization, Boston, MA |
- |
10 - 13 September 2019, CAR-TCR Summit Boston 2019, Boston, MA |
- |
7 - 8 October 2019, 9th annual Partnership Opportunities in Drug Delivery, Boston, MA |
- |
9 October 2019, The Cell & Gene Therapy Strategy Meeting Europe, Zurich, Switzerland |
- |
15 – 16 October 2019, 9th Annual Orphan Drugs and Rare Diseases conference, London, UK |
- |
15 – 17 October 2019, Gene Therapy for Rare Disorders Europe 2019, London, UK |
- |
21 – 22 October 2019, NORD's 2019 Rare Diseases & Orphan Products Breakthrough Summit, Washington, D.C. |
- |
21 – 25 October 2019, XXVII Congress of the European Society of Gene and Cell Therapy (ESGCT), Barcelona, Spain |
- |
24 – 25 October 2019, 5th Annual Cell & Gene Therapy Congress, London, UK |
- |
29 – 31 October 2019, Cell and Gene Therapy Manufacturing Forum event, London, UK |
- |
19 – 20 November 2019, 3rd Annual Ophthalmic Drugs Conference - gene therapy for eye diseases, London, UK |
- |
12 - 15 May 2020, American Society of Gene and Cell Therapy (ASGCT) 23th Annual Meeting, Boston, MA |
- |
31 March - 2 April 2020, 15th Annual World Advanced Therapies Congress, London, UK |
- |
20 – 23 October 2019, XXVIII Congress of the European Society of Gene and Cell Therapy (ESGCT), Edinburgh UK |
|
Read more... |
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net, Ebola Virus Net, Chikungunya Virus Net and Zika Virus Net.
|
To unsubscribe from the Newsletter, please login and edit your subscription details, or {unsubscribe}unsubscribe direct{/unsubscribe}, or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}. |
|